levetiracetam + sulthiame

Levetiracetam + sulthiame is a combination of two antiepileptic drugs used in the management of epilepsy, particularly as adjunctive therapy for focal epilepsies and benign epilepsy with centrotemporal spikes (BECTS) in children. Levetiracetam is a pyrrolidone derivative that acts primarily by binding to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release, and inhibiting N-type calcium channels. Sulthiame is a carbonic anhydrase inhibitor that reduces neuronal excitability through inhibition of carbonic anhydrase activity, leading to altered ionic balance and decreased seizure susceptibility. Both agents are small molecules with distinct mechanisms, often used when monotherapy is insufficient or as part of polytherapy for refractory cases[1][2][3][4].